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A B S T R A C T   
Human CtIP was originally identified as an interactor of the retinoblastoma protein and BRCA1, two bona fide 
tumour suppressors frequently mutated in cancer. CtIP is renowned for its role in the resection of DNA double- 
strand breaks (DSBs) during homologous recombination, a largely error-free DNA repair pathway crucial in 
maintaining genome integrity. However, CtIP-dependent DNA end resection is equally accountable for alter-
native end-joining, a mutagenic DSB repair mechanism implicated in oncogenic chromosomal translocations. In 
addition, CtIP contributes to transcriptional regulation of G1/S transition, DNA damage checkpoint signalling, 
and replication fork protection pathways. In this review, we present a perspective on the current state of 
knowledge regarding the tumour-suppressive and oncogenic properties of CtIP and provide an overview of their 
relevance for cancer development, progression, and therapy.   
1. Introduction 
Human CtIP is an 897-amino acid nuclear adaptor protein with 
multiple roles in DNA metabolism and genome stability [1,2]. Initially 
thought to function exclusively as a regulator of gene expression, 
continued research has revealed that CtIP plays a significant role in DNA 
double-strand break (DSB) repair pathway choice, with opposing con-
sequences for genome stability and tumorigenesis. Herein, we review 
the current literature on CtIP’s molecular and biological activities with a 
particular focus on their clinical relevance for cancer progression and 
treatment outcomes. 
1.1. CtIP: History at a glance 
Human CtIP was first isolated in 1998 using yeast two-hybrid 
screening experiments performed in four independent laboratories. 
Schaeper et al. identified CtIP as an interacting protein of the oncogenic 
transcriptional corepressor CtBP. Of note, CtIP binds CtBP through a 
PLDLS motif conserved among E1A proteins of human adenoviruses [3]. 
Fusco et al. called the same polypeptide RIM (encoded by RBBP8 located 
at 18q11.2) by virtue of its ability to interact with the Rb tumour sup-
pressor protein via a conserved LxCxE Rb-binding motif [4]. Shortly 
thereafter, two studies reported CtIP to specifically interact with the 
BRCT domain of BRCA1 [5,6]. Together, these early findings implicated 
CtIP in suppressing tumorigenesis, possibly by regulating the tran-
scription of cell cycle-related genes [7]. 
To date, orthologs of human CtIP have been characterised in several 
uni- and multicellular organisms, including S. cerevisiae (Sae2/Com1), 
S. pombe (Ctp1), P. tetraurelia (PtCtIP), C. elegans (COM-1), and 
A. thaliana (AtCOM1). Remarkably, CtIP deficiency results in impaired 
repair of DSBs in somatic cells and during meiosis [2,8–11]. It is now 
well established that CtIP associates with the MRE11-RAD50-NBS1 
(MRN) nuclease complex to initiate 5’-3’ resection of broken DNA 
ends, a critical determinant of DSB repair pathway choice [12–14]. 
1.2. Architecture and Protein Interaction Network of CtIP 
CtIP is largely intrinsically disordered with two conserved domains 
located at the N- and C-terminus of the protein (Fig. 1) [1]. The N-ter-
minal domain is comprised of coiled-coil heptad repeats mediating CtIP 
dimerisation [15,16]. In addition, a short α-helical motif preceding the 
coiled-coil region promotes CtIP tetramerisation [17–19]. The C-termi-
nal Sae2-like domain harbours a highly conserved DNA binding motif, 
which enables CtIP to form protein-DNA filaments and promote DNA 
bridging [18–20]. Two independent studies reported that CtIP exhibits 
intrinsic structure-specific endonuclease activity mediated by two 
distinct catalytic sites, a topic that is still controversially discussed in the 
literature [2,1,18,21–23]. 
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Typical for multivalent adaptor proteins, CtIP contains various short 
linear sequence motifs facilitating interactions between protein-binding 
partners, some of which are governed by CtIP phosphorylation (Fig. 1) 
[2,24]. For instance, CDK-mediated phosphorylation of CtIP at S327 is a 
prerequisite for the binding of BRCA1 BRCT domains and has been 
proposed to speed up DSB resection in S/G2-cells [25,26]. In contrast, 
CDK-dependent phosphorylation of CtIP at T847 is indispensable for 
DNA end resection, most likely by fostering MRN-CtIP complex forma-
tion [23,27]. Two additional CDK phosphorylation sites in CtIP, S276 
and T315, are required for the binding of PIN1, a unique peptidyl-prolyl 
cis-trans isomerase found to be overexpressed in many cancers and to 
promote uncontrolled cell proliferation [28–30]. CtIP isomerisation has 
been proposed to facilitate CUL3-KLHL15-mediated CtIP ubiquitination 
and subsequent proteasomal degradation to limit CtIP’s resection ac-
tivity [28,31]. APC/C-Cdh1 recognizes CtIP through a conserved KEN 
box motif and targets CtIP for ubiquitin-proteasome-mediated degra-
dation in G2, presumably to prevent inappropriate DNA resection in 
mitosis [32]. Following genotoxic insults, CtIP phosphorylation at T859 
by the apical DNA damage response (DDR) kinases ATM and ATR is 
important for stable chromatin association of CtIP and efficient DSB 
processing [33,34]. Remarkably, a recent biochemical study reported 
that CtIP phosphorylation on T847 and T859 is critical for MRN 
endonuclease-mediated removal of DNA-PK from DNA ends to allow 
resection and repair of DSBs by HR [35]. CtIP also directly associates 
with FANCD2, the central mediator of the Fanconi Anemia tumour 
suppressor pathway responsible for the repair of DNA interstrand 
crosslinks [36,37]. Finally, CtIP structural interaction with the breast 
cancer oncogene LMO4 has been hypothesised to sequester CtIP away 
from DNA repair complexes [38]. 
CtIP expression levels are tightly regulated throughout the cell cycle, 
remaining low in G1 and increasing in S and G2 phases, when sister 
chromatids are available as a template for HR repair [1,8]. Besides the 
aforementioned mechanisms controlling CtIP protein turnover by 
ubiquitin-proteasomal processing, there is accumulating evidence that 
CtIP abundance is also regulated at the level of transcription. Liu et al. 
showed that CtIP can bind to its own promoter, upregulating its 
expression during G1/S progression (Fig. 2) [39]. Moreover, several 
microRNAs have been shown to silence CtIP expression. Martin et al. 
reported that miR-335-mediated suppression of CtIP is released 
following ionising radiation (IR)-induced ATM activation, classifying 
miR-335 as a potential radiosensitiser for clinical use [40,41]. Similarly, 
CtIP transcripts are negatively regulated by miR-19, a member of the 
miR-17~92 cluster whose expression is upregulated in many cancer 
types [42,43]. More recently, downregulation of CtIP by miR223-3p was 
identified as a protective mechanism against chromosomal rearrange-
ments in developing haematopoietic cells [44]. 
2. Versatile Roles of CtIP in Genome Maintenance 
CtIP’s ability to specifically interact with multiple binding partners 
(Fig. 1) correlates well with its function in diverse genome maintenance 
mechanisms, including cell cycle control, DNA damage repair, and DNA 
replication (Fig. 2) [1,2,8]. 
2.1. Transcriptional regulation and cell cycle checkpoints 
Early studies connecting the CtIP-CtBP corepressor complex to Rb 
family and BRCA1 proteins suggested a prominent role of CtIP in tran-
scriptional regulation of cell cycle events (Fig. 2) [2]. For instance, the 
interaction between CtIP and Rb has been shown to alleviate 
Rb-mediated transcriptional repression of certain E2F target genes (e.g. 
CCND1), thus facilitating G1/S transition [39,45]. Conversely, in 
response to DNA damage, CtIP was reported to bind to the promoter and 
induce the expression of the CDK inhibitor p21, hence blocking G1/S 
transition [46]. Moreover, binding of CtIP-CtBP to BRCA1 has been 
implicated in preventing p21 promoter transactivation by BRCA1, while 
DNA damage-induced disruption of the BRCA1-CtIP interaction could 
relieve p21 and GADD45A transcriptional repression [47,48]. Similarly, 
association of CtIP with BRCA1 and the BRCA1-binding transcriptional 
repressor ZBRK1 negatively regulates the expression of pro-tumorigenic 
factors such as ANG1 and HMGA2, and loss of this heterotrimeric 
complex has been shown to enhance mammary tumorigenesis [49,50]. 
In addition, binding of the CtIP-LMO4 complex to BRCA1 inhibits 
BRCA1-mediated transcriptional activation [51]. Consequently, CtIP 
appears to exert dual control over gene expression and promoter activ-
ities depending on its binding partners. 
In contrast, Yu and Chen first demonstrated that formation of the 
CtIP-BRCA1 complex in G2 is required for the IR-induced phosphory-
lation of Chk1 and activation of the G2/M transition checkpoint [25]. In 
agreement with these findings, it was recently shown that CtIP promotes 
G2/M arrest through ATR-Chk1 activation rather than by induction of 
the p53-p21/GADD45a pathway [52]. ATR-Chk1 signalling in response 
to DNA damage is initiated by the recruitment of ATR to RPA-coated 
ssDNA tracks, key intermediates formed during DSB resection (Fig. 2) 
[53]. Therefore, while CtIP regulates G1/S transition mostly at the level 
of transcription, its G2/M checkpoint function is primarily mediated by 
DNA end resection. 
2.2. DNA end resection and DSB repair pathway choice 
In a process commonly referred to as ‘DNA end resection’, CtIP as-
sociates with the MRN complex to promote limited (5’-3’) nucleolytic 
processing of DSBs, which commits cells to homology-directed repair 
mechanisms (HR, SSA, and a-EJ) and prevents repair by c-NHEJ (Fig. 2) 
Fig. 1. Human CtIP, a polyvalent adaptor protein. 
CtIP is composed of a tetramerisation motif (Tet) and an extended coiled-coil region at the N-terminus, an unstructured central region and an Sae2-like domain at the 
C-terminus. Two non-canonical nuclease motifs harbouring residues implicated in catalytic activity are highlighted by asterisks. Short linear sequence motifs pro-
moting specific protein interactions and DNA binding are indicated by dashed lines. CtIP interactors classified as tumour suppressors and oncogenes are highlighted 
in green and red letters, respectively. Selected serine/threonine (S/T) phosphorylation sites are indicated. CtIP C-terminal truncation variants identified in Jawad and 
Seckel (SCKL2) syndrome patients [83] are indicated by jagged lines. Three RBBP8 mutations (Q643P, E804Δ and R805G) associated with early-onset breast cancer 
(BC) are indicated by straight lines [78]. 
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[12,14,54,55]. However, while HR faithfully restores the original DNA 
sequence at the break site in most cases, SSA and a-EJ frequently result 
in deletions and are associated with pathological chromosome rear-
rangements [14]. Importantly, BRCA1, in complex with its constitutive 
partner BARD1, counteracts 53BP1 chromatin accumulation to facilitate 
CtIP-mediated resection, thereby tipping the balance towards the 
exclusion of c-NHEJ and induction of HR, especially for breaks 
encountered during DNA replication [56,57]. Extended resection is 
carried out by dedicated DNA nucleases and helicases, most notably 
EXO1, DNA2, and BLM [13]. Interestingly, CtIP restrains EXO1 exonu-
clease activity but accelerates BLM/DNA2-mediated DNA cleavage, 
presumably via direct protein-protein interactions, thus coordinating 
both short- and long-range resection processes [60–62]. Resulting 
3’-ssDNA overhangs are rapidly coated by the heterotrimeric RPA 
complex, creating a platform for ATR-Chk1 signalling (Fig. 2) [63]. The 
choice between error-free HR and mutagenic a-EJ and SSA pathways 
mainly happens downstream of DSB resection [14,64,65]. In the pres-
ence of a homologous DNA template, preferentially the intact sister 
chromatid, BRCA2 mediates RAD51 filament assembly on ssDNA to 
promote subsequent strand invasion and exchange steps of HR. When 
HR is inappropriate, exposure of microhomologies between resected 
DNA arms can drive RPA removal and gap-filling synthesis by Polθ 
associated with a-EJ. Alternatively, RAD52-mediated annealing of 
complementary ssDNA ends between repeated sequences occurs during 
SSA. Remarkably, DSB resection and repair activities of CtIP have also 
been reported outside S/G2 phases of the cell cycle. For instance, 
Löbrich and colleagues could demonstrate that resection-dependent 
c-NHEJ of IR-induced DSBs in G1-cells contributes to chromosomal 
translocations and is induced by polo-like kinase 3 (PLK3)-dependent 
CtIP-S327 phosphorylation and interaction between CtIP and BRCA1 
[66,67]. 
In summary, CtIP-mediated DNA end resection is mostly required for 
accurate repair of DSBs by HR, but also allows SSA, a-EJ and c-NHEJ to 
create mutagenic repair products, ranging from simple deletions to 
complex chromosomal rearrangements. 
2.3. DNA replication stress 
There is substantial evidence that besides its fundamental role in DSB 
resection, CtIP is engaged in different processes safeguarding genome 
Fig. 2. CtIP at the crossroads of multiple genome maintenance mechanisms. 
Upper left, CtIP is implicated in the transcriptional regulation of several genes during G1/S transition. Upon interaction with CtIP, Rb is released from E2F-responsive 
promoters, where CtIP binds and activates gene expression. Under normal conditions, p21 is repressed by BRCA1-CtIP-CtBP. DNA damage disrupts this complex and 
induces the recruitment of CtIP to p21 promoter elements, enhancing p21 expression. Middle, In response to DSBs, CtIP associates with the MRN complex and 
stimulates MRE11 endonuclease activity to initiate bidirectional DNA end resection, using EXO1 or BLM/DNA2 in the 5’-3’ direction away from the DSB, and 
MRE11’s exonuclease in the 3’-5’ direction towards the DSB end (not shown). In addition, CtIP/MRN-mediated endonucleolytic cleavage displaces DNA-PK 
(composed of the Ku70-80 heterodimer and DNA-PKcs) from broken DNA ends. These processes effectively suppress c-NHEJ. Ensuing resection of the 5’ strand 
leads to the exposure of 3’-ssDNA overhangs, which commits DSB repair to homology-directed pathways (HR, a-EJ or SSA) and activates ATR-Chk1 signalling. HR 
relies on the sequential actions of BRCA1-BARD1 and BRCA2 to direct RAD51-dependent homologous DNA template search and ensure accurate DSB repair. In the 
absence of HR or when HR repair is inappropriate due to the lack of a sister chromatid template, mutagenic repair pathways such as Polθ-dependent a-EJ or RAD52- 
mediated SSA are activated. Upper right, Following DNA replication stress, CtIP is recruited to stalled replication forks, where it inhibits DNA2-dependent over- 
resection of nascent DNA, presumably via endonucleolytic incision of the reversed 5’-strand. Therein, CtIP acts synergistically with BRCA1, which protects reversed 
forks from MRE11-mediated degradation. 
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integrity in response to DNA replication stress [68,69]. Cortez and col-
leagues repeatedly found CtIP to be enriched at active replication forks 
[70,71], presumably through its direct interaction with PCNA (Fig. 1) 
[72]. Yeo et al. reported that CtIP binding to FANCD2 facilitates CtIP 
relocation to damaged replication forks, thereby promoting fork restart 
and preventing new origin firing during fork recovery [73]. The Hen-
drickson laboratory showed that CtIP maintains telomere integrity 
during DNA replication via a similar mechanism [74]. The role of CtIP at 
stalled forks following hydroxyurea (HU)-induced replication stress is 
subject to controversy. Initially, it was shown that CtIP promotes the 
degradation of stalled forks by stimulating MRE11 and EXO1 nuclease 
activities [75,76]. Our group later demonstrated that CtIP protects 
reversed forks from nucleolytic degradation by DNA2 (Fig. 2) [77], a 
finding that was independently confirmed by a study from the Sørensen 
group [78]. However, while our data implicated CtIP’s endonuclease 
activity in fork protection, Zarrizi et al. proposed that CtIP suppresses 
fork degradation by counteracting FBH1-mediated removal of RAD51 
from stalled forks [77,78]. In addition, we found that CtIP-dependent 
stimulation of MRE11 endonuclease activity (via pT847) and 
CtIP-BRCA1 interaction (via pS327) are largely dispensable for fork 
protection [77]. Of note, recent data suggest that CtIP-BRCA1 interac-
tion is critical for the initation of transcription-associated HR repair of 
DSBs arising at stalled replication sites upon formation of DNA-RNA 
hybrids, also termed R-loops [79]. Remarkably, efficient resolution of 
R-loops was shown to rely on CtIP’s endonuclease activity [80]. Recent 
work from the Morris laboratory established that PIN1-induced 
conformational change of the BRCA1-BARD1 complex is required for 
fork protection, but not for HR repair. On this basis, it would be inter-
esting to determine whether a similar separation-of-function mechanism 
applies to CtIP, an established PIN1 target [28,81]. Interestingly, we 
could further reveal that CtIP acts in a synergistic or additive manner 
with BRCA1 in protecting nascent DNA strands from nucleolytic 
degradation, which potentially contributes to the observed synthetic 
sick/lethal relationship between CtIP and BRCA1 [77]. Together, these 
findings highlight an important HR-independent function of CtIP in 
maintaining genome stability. 
3. CtIP’s dual role in tumorigenesis and cancer progression 
Deregulation of the cell cycle and high levels of genomic instability 
are not only characteristics of cancer but also a driving force of tumor-
igenesis [82]. Therefore, CtIP-ascribed molecular activities have mostly 
been implicated in tumour suppression. This general assumption has 
gained further support by an early genetic study in mice showing that 
homozygous deletion of Ctip causes early embryonic lethality, while 
Ctip+/- heterozygosity renders mice prone to malignancy, most likely 
due to CtIP haploid insufficiency [45]. This paradigm has recently been 
challenged by several studies indicating that CtIP has oncogenic po-
tential facilitating tumorigenesis. 
3.1. CtIP mutations and genomic alterations in human disease 
Given that Ctip is indispensable for viability in mice [45,58], it is not 
surprising that complete loss-of-function mutations in CtIP/RBBP8 have 
not been reported in man. Rare, biallelic hypomorphic CtIP variants 
translating into C-terminal truncated proteins cause Jawad and Seckel 
syndromes (Fig. 1), genetically heterogeneous conditions characterised 
by severe microcephaly and mental retardation, but no overt cancer 
predisposition [83]. Interestingly, Seckel patient-derived cell lines 
commonly display defects in ATR-dependent DNA damage signalling, 
certainly a well-established phenotype of CtIP-deficient cells [84,85]. 
Germline mutations in BRCA1 or BRCA2 greatly increase breast and 
ovarian cancer risk in patients [86]. Early studies demonstrated that 
tumour-associated mutations within the BRCA1 BRCT domains can 
disrupt its interaction with CtIP [2,6]. However, loss of BRCA1-CtIP 
interaction in mouse models expressing S327A mutant CtIP neither 
compromises genomic stability nor enhances tumour susceptibility [58, 
59]. Therefore, it remains an open question whether and how the 
BRCA1-CtIP interaction contributes to cancer development. Rebbeck 
et al. revealed that inherited clusters of SNPs at the CtIP locus (‘CtIP 
haplotypes’) are associated with modified breast, but not ovarian, can-
cer risk in women with BRCA1 mutations, supporting a role for CtIP in 
tumour suppression [87]. Moreover, two different, deleterious RBBP8 
frameshift variants were recently detected in two early-onset breast 
cancer patients without BRCA1 mutation, although their relative 
contribution to pathogenicity was not determined [88]. A recent study 
identified twelve rare germline CtIP mutations in Danish cohorts of 
early-onset breast cancer patients negative for high risk BRCA1/2 mu-
tations [78]. Remarkably, the CtIP-E804Δ variant, lacking a single 
amino acid within the C-terminal region (Fig. 1), caused severe defects 
in response to HU-induced replication stress, including deleterious 
nucleolytic degradation of reversed forks, but were proficient in DNA 
end resection and HR [78]. Owing to an exonic (A)9 mononucleotide 
repeat tract prone to mutation in mismatch repair-deficient tumours, 
RBBP8 has been described as a prominent target for microsatellite 
instability (MSI)-induced mutations in colorectal, endometrial and 
myeloid malignancies [89–91]. 
Genomic alteration analyses in patient samples across 32 different 
cancer types reveal that CtIP/RBBP8 is mainly amplified, but rarely 
mutated or deleted, which is in marked contrast to the situation of 
BRCA1 (Fig. 3A). CtIP amplification is most prevalent in pancreatic 
cancers, with 16% of profiled tumours from two publicly available 
datasets showing genomic alterations in RBBP8 (Fig. 3A and B). 
Although CtIP is predominantly amplified in pancreatic cancers, a few 
missense CtIP mutations of unknown significance have been reported 
that could potentially drive pancreatic tumorigenesis (Fig. 3B) [5]. 
Furthermore, Kaplan-Meier survival analysis in a study of 178 patients 
reveals that high expression of CtIP is significantly linked to poor 
prognosis in pancreatic adenocarcinoma (PAAD), suggesting an onco-
genic activity of CtIP in these tumours (Fig. 3C). 
Interestingly, RBBP8 amplification was previously shown to occur 
mutually exclusive with BRCA1 and RB1 inactivation in high grade se-
rous ovarian cancer, further supporting the idea of RBBP8 acting as a 
candidate oncogene in certain tumour types [92]. Rb is a master nega-
tive regulator of cell cycle progression and numerous cancers are char-
acterised by Rb inactivation [93]. It is therefore conceivable that CtIP 
upregulation could drive tumorigenesis in a similar manner to RB1 
loss-of-function. Presumably, CtIP-mediated Rb inhibition and subse-
quent de-repression of E2F-responsive genes such as CCND1 could 
promote sustained proliferation by facilitating G1/S transition [39]. A 
similar relationship between CtIP and the Rb pathway has recently been 
proposed to contribute to the development of plasma cell myeloma, 
wherein high RBBP8 expression correlates with poor survival and 
tumour recurrence in patients [94]. Accordingly, CtIP downregulation 
by promoter methylation was found to correlate with a more favourable 
prognosis in bladder cancer [95]. Yu et al. reported that CtIP expression 
was upregulated in gastric cancer and adjacent neoplastic tissues as 
compared with normal tissue [96]. CtIP overexpression in gastric cancer 
was accompanied by increased CtIP-CtBP-BRCA1-mediated p21 sup-
pression, which could promote G1/S transition and sustained prolifer-
ation [96]. Although CtIP expression levels did not significantly affect 
overall survival in those patients, CtIP-mediated proliferative activity, 
presumably through p21 repression and CCND1 upregulation (Fig. 2), 
was associated with worse prognosis at early stages of gastric cancer 
development [96]. Consistently, CtIP is frequently amplified in oeso-
phageal carcinoma (ESCA) and stomach adenocarcinoma (STAD) 
(Fig. 3A). Other studies, however, have found that CtIP expression is 
frequently downregulated in breast cancer patients and that low 
expression is combined with unfavourable prognosis and metastasis 
formation [97–99], which is markedly different from what is observed in 
pancreatic cancer patients (Fig. 3C). Thus, the relationship between CtIP 
expression and disease progression appears to be intricately linked with 
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tumour type, possibly reflecting the relative importance of distinct CtIP 
functions in the pathogenesis of different cancers. 
3.2. Anti- and pro-tumorigenic properties of CtIP 
Owing to its fundamental role in HR, CtIP may, albeit to a limited 
extent, be involved in tumour suppression through preventing the 
accumulation of cancer-enabling mutations and genome instability 
arising from erroneous repair of DSBs [1,2,82]. Originally, CtIP has been 
postulated as a haploinsufficient tumour suppressor based on the 
shortened lifespan of Ctip+/- heterozygous mice, which succumbed to 
multiple tumours, predominantly large B-cell lymphomas [45]. How-
ever, a recent independent study could not recapitulate this finding, 
showing instead that tumour-free survival is indistinguishable between 
wild-type mice and mice harbouring a single null allele of the Ctip gene 
[100]. Moreover, and considerably different from conditional Brca1-null 
females, mammary-specific biallelic inactivation of Ctip did not induce 
breast tumours [100]. On the contrary, Reczek et al. discovered that Ctip 
loss-of-function slowed down mammary tumorigenesis in p53-deficient 
mice, suggesting an oncogenic activity in CtIP [100]. A conceivable 
mechanistic explanation for CtIP-driven malignant transformation is 
that CtIP-dependent resection promotes chromosomal translocations 
and telomere fusions through a-EJ (Fig. 2) [101–103]. In line with this 
hypothesis, Srinivasan et al. recently reported that miR223-3p-mediated 
CtIP downregulation prevents mutagenic a-EJ and, thus, chromosomal 
translocations in normal cells, whilst reduced expression of miR223-3p 
is frequently observed in BRCA1-deficient cancer cells [44]. 
Maintenance of telomere length and integrity is essential for pre-
venting genomic instability and oncogenic transformation [104]. Due to 
the formation of secondary structures and the repetitive nature of telo-
meric DNA sequences, telomere replication is a complex process that can 
lead to replication fork stalling and collapse [105]. CtIP was recently 
shown to protect replicating telomeres from aberrant shortening and 
fusions, by rescuing stalled replication forks and promoting 
HR-mediated DSB repair of collapsed forks [74]. In addition, the func-
tion of CtIP in protecting nascent DNA at stalled forks from nucleolytic 
degradation (Fig. 2) may contribute to the protection of replicating 
telomeres [77]. Furthermore, work from the Scully laboratory revealed 
that CtIP acts independently from BRCA1 in preventing the formation of 
microhomology-mediated small tandem duplications, a genome-wide 
DNA rearrangement signature produced by aberrant processing of stal-
led replication forks and typically found in BRCA1-deficient cancers 
[106,107]. Therefore, it is tempting to speculate that CtIP, at least in 
parts, counteracts tumorigenesis via its role in alleviating replication 
stress-induced genomic instability. 
4. Clinical relevance of targeting CtIP for cancer therapy 
Despite its ambiguous role in tumorigenesis, CtIP has prognostic 
value in several types of cancer and could serve as a predictive 
biomarker for treatment response in selected patients [94,95,98,99]. As 
previously mentioned, low RBBP8 expression correlates with breast 
Fig. 3. RBBP8 genomic alterations and expression analysis in cancer. 
(A) Cross-cancer summary of mutations and copy number variations of RBBP8 and BRCA1 across 32 cancer types based on patient data from the combined TCGA 
PanCancer Atlas [126] available on cBioPortal (http://www.cbioportal.org/). (B) RBBP8 amplification is the most prevalent type of genomic alteration observed in 
two independent pancreatic cancer studies (TCGA, PanCancer Atlas for pancreatic adenocarcinoma (PAAD); UTSW, NatComm, 2015) [126,127]. (C) Kaplan-Meier 
plots using mRNA expression data from primary tumour samples of the TCGA Pan-Cancer Atlas PAAD study [126] were generated in UCSC Xena [128]. High CtIP 
expression correlates with unfavourable prognosis in PAAD, both for overall (p-value = 0.0032) and progression-free (p-value = 0.0092) survival. For this analysis, 
patient samples were divided into two RBBP8 expression groups, separated by the median: “High” (expression values ≥ 9.350) and “Low” (expression values 
< 9.350). 
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cancer aggressiveness and poor response to hormonal therapy in breast 
cancer [97,99]. However, reduced CtIP protein levels in luminal breast 
cancers are associated with better response to DNA-damaging chemo-
therapy [99], presumably due to a decreased DSB repair capacity. In 
bladder cancer, CtIP promoter methylation, leading to gene silencing, is 
linked to better prognosis and can be readily detected in non-invasive 
urine tests [95]. Platinum-based drugs are commonly used for treating 
bladder cancer [108] and have demonstrated improved efficacy in 
BRCA1/2-mutated, HR-deficient tumours [109,110]. Therefore, it is 
plausible that reduced CtIP expression and ensuing HR defects could 
underlie improved response to cisplatin treatment in bladder cancer. In 
contrast, selective CtIP inhibition with yet-to-be-discovered targeting 
molecules may synergise with DNA-damaging drugs, particularly in 
tumours displaying CtIP amplification such as highly aggressive 
pancreatic cancer (Fig. 3). 
Genomic instability and acquired DNA repair defects are common 
features of many cancers and can be therapeutically exploited based on 
the concept of synthetic lethality [82,110–113]. A paradigm example is 
the use of PARP inhibitors for treating BRCA1/2-mutated breast and 
ovarian cancer [114–116]. A major caveat of PARPi therapy is the 
development of treatment resistance due to secondary mutations leading 
to the restoration of BRCA1/2 or re-establishment of DNA end resection 
[117,118]. Therefore, selectively targeting additional DNA damage 
response components, including CtIP, could potentially re-sensitise 
these cancers to PARPi [119]. CtIP depletion sensitises breast cancer 
cells to PARPi, presumably by suppressing HR, suggesting that CtIP 
could be an interesting biomarker for predicting disease progression and 
therapy response in breast cancer [98]. Furthermore, impaired recruit-
ment of CtIP to DSBs upon CHD1 loss was shown to sensitise prostate 
cancer cells to PARPi [120]. Ceccaldi et al. reported that HR-deficient 
ovarian cancers strongly rely on Polθ-mediated a-EJ to repair DSBs 
arising at collapsed forks, thereby contributing to tumour development 
[112,121,122]. Thus, blocking a-EJ via Polθ or CtIP inhibition could be a 
valid synthetic lethal strategy for selective killing of BRCA1-deficient 
tumours. We have recently reported that CtIP and BRCA1 operate in 
separate fork protection pathways, thus providing an alternative 
mechanism explaining the potential synthetic lethal relationship be-
tween CtIP and BRCA1 [77]. A recent synthetic lethality screen for 
candidate PARPi sensitivity genes in HR-proficient cells identified 
BRD4, a chromatin-binding protein frequently overexpressed in several 
types of cancers [123,124]. Remarkably, BRD4 enrichment at the RBBP8 
promoter and enhancer, and, thus, CtIP expression, were significantly 
decreased upon BRD4 inhibition, which ultimately caused HR deficiency 
and PARPi hypersensitivity [123]. In our opinion, these findings provide 
a clear rationale for the development of CtIP targeting approaches to 
potentially improve existing cancer therapies and counteract acquired 
PARPi resistance in selected cancers. 
5. Conclusions 
CtIP is a multifaceted player in DNA repair and genomic stability and 
acts as a “double-edged sword” in cancer. Its diverse functions in tran-
scriptional regulation, DSB repair and replication stress response have 
been implicated in different aspects of tumorigenesis, leading to positive 
or unfavourable outcomes depending on cancer type and biological 
context. Thus, CtIP (RBBP8) can be classified as ‘double agent’, a term 
coined for genes harbouring both tumour suppressive and oncogenic 
functions, depending on the respective alterations and cellular context, 
and often functioning as central hubs in protein interaction networks 
[125]. Further research will be required to more clearly define the role 
of CtIP in maintaining the balance between oncogenesis and tumour 
suppression, with potential implications for cancer prognosis and 
therapy. 
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[26] A. Cruz-García, A. López-Saavedra, P. Huertas, BRCA1 Accelerates CtIP-Mediated 
DNA-End Resection, Cell Reports. 9 (2014) 451–459, https://doi.org/10.1016/j. 
celrep.2014.08.076. 
[27] P. Huertas, S.P. Jackson, Human CtIP Mediates Cell Cycle Control of DNA End 
Resection and Double Strand Break Repair, J. Biol. Chem. 284 (2009) 9558–9565, 
https://doi.org/10.1074/jbc.M808906200. 
[28] M. Steger, O. Murina, D. Hühn, L.P. Ferretti, R. Walser, K. Hänggi, L. Lafranchi, 
C. Neugebauer, S. Paliwal, P. Janscak, B. Gerrits, G. Del Sal, O. Zerbe, A. 
A. Sartori, Prolyl Isomerase PIN1 Regulates DNA Double-Strand Break Repair by 
Counteracting DNA End Resection, Molecular Cell. 50 (2013) 333–343, https:// 
doi.org/10.1016/j.molcel.2013.03.023. 
[29] X.Z. Zhou, K.P. Lu, The isomerase PIN1 controls numerous cancer-driving 
pathways and is a unique drug target, Nat Rev Cancer. 16 (2016) 463–478, 
https://doi.org/10.1038/nrc.2016.49. 
[30] W. Pu, Y. Zheng, Y. Peng, Prolyl Isomerase Pin1 in Human Cancer: Function, 
Mechanism, and Significance, Front. Cell Dev. Biol. 8 (2020), https://doi.org/ 
10.3389/fcell.2020.00168. 
[31] L.P. Ferretti, S.-F. Himmels, A. Trenner, C. Walker, C. von Aesch, 
A. Eggenschwiler, O. Murina, R.I. Enchev, M. Peter, R. Freire, A. Porro, A. 
A. Sartori, Cullin3-KLHL15 ubiquitin ligase mediates CtIP protein turnover to 
fine-tune DNA-end resection, Nat Commun. 7 (2016) 1–16, https://doi.org/ 
10.1038/ncomms12628. 
[32] L. Lafranchi, H.R. de Boer, E.G. de Vries, S.-E. Ong, A.A. Sartori, M.A. van Vugt, 
APC/CCdh1 controls CtIP stability during the cell cycle and in response to DNA 
damage, The EMBO Journal 33 (2014) 2860–2879, https://doi.org/10.15252/ 
embj.201489017. 
[33] S.E. Peterson, Y. Li, F. Wu-Baer, B.T. Chait, R. Baer, H. Yan, M.E. Gottesman, 
J. Gautier, Activation of DSB Processing Requires Phosphorylation of CtIP by 
ATR, Molecular Cell. 49 (2013) 657–667, https://doi.org/10.1016/j. 
molcel.2012.11.020. 
[34] H. Wang, L.Z. Shi, C.C.L. Wong, X. Han, P.Y.-H. Hwang, L.N. Truong, Q. Zhu, 
Z. Shao, D.J. Chen, M.W. Berns, J.R. Yates, L. Chen, X. Wu, The Interaction of CtIP 
and Nbs1 Connects CDK and ATM to Regulate HR–Mediated Double-Strand Break 
Repair, PLoS Genet. 9 (2013), e1003277, https://doi.org/10.1371/journal. 
pgen.1003277. 
[35] R.A. Deshpande, L.R. Myler, M.M. Soniat, N. Makharashvili, L. Lee, S.P. Lees- 
Miller, I.J. Finkelstein, T.T. Paull, DNA-dependent protein kinase promotes DNA 
end processing by MRN and CtIP, Science Advances. 6 (2020), eaay0922, https:// 
doi.org/10.1126/sciadv.aay0922. 
[36] O. Murina, C. von Aesch, U. Karakus, L.P. Ferretti, H.A. Bolck, K. Hänggi, A. 
A. Sartori, FANCD2 and CtIP Cooperate to Repair DNA Interstrand Crosslinks, Cell 
Reports. 7 (2014) 1030–1038, https://doi.org/10.1016/j.celrep.2014.03.069. 
[37] J. Unno, A. Itaya, M. Taoka, K. Sato, J. Tomida, W. Sakai, K. Sugasawa, M. Ishiai, 
T. Ikura, T. Isobe, H. Kurumizaka, M. Takata, FANCD2 Binds CtIP and Regulates 
DNA-End Resection during DNA Interstrand Crosslink Repair, Cell Reports. 7 
(2014) 1039–1047, https://doi.org/10.1016/j.celrep.2014.04.005. 
[38] P.H. Stokes, C.W. Liew, A.H. Kwan, P. Foo, H.E. Barker, A. Djamirze, V. O’Reilly, 
J.E. Visvader, J.P. Mackay, J.M. Matthews, Structural Basis of the Interaction of 
the Breast Cancer Oncogene LMO4 with the Tumour Suppressor CtIP/RBBP8, 
Journal of Molecular Biology. 425 (2013) 1101–1110, https://doi.org/10.1016/j. 
jmb.2013.01.017. 
[39] F. Liu, W.-H. Lee, CtIP Activates Its Own and Cyclin D1 Promoters via the E2F/RB 
Pathway during G1/S Progression, Molecular and Cellular Biology. 26 (2006) 
3124–3134, https://doi.org/10.1128/MCB.26.8.3124-3134.2006. 
[40] N.T. Martin, K. Nakamura, R. Davies, S.A. Nahas, C. Brown, R. Tunuguntla, R. 
A. Gatti, H. Hu, ATM–Dependent MiR-335 Targets CtIP and Modulates the DNA 
Damage Response, PLOS Genetics. 9 (2013), e1003505, https://doi.org/10.1371/ 
journal.pgen.1003505. 
[41] A.-H. Rezaeian, H. Khanbabaei, G.A. Calin, Therapeutic Potential of the 
miRNA–ATM Axis in the Management of Tumor Radioresistance, Cancer Res. 80 
(2020) 139–150, https://doi.org/10.1158/0008-5472.CAN-19-1807. 
[42] D. Hühn, A.N. Kousholt, C.S. Sørensen, A.A. Sartori, miR-19, a component of the 
oncogenic miR-17~92 cluster, targets the DNA-end resection factor CtIP, 
Oncogene. 34 (2015) 3977–3984, https://doi.org/10.1038/onc.2014.329. 
[43] L.-L. Fang, X.-H. Wang, B.-F. Sun, X.-D. Zhang, X.-H. Zhu, Z.-J. Yu, H. Luo, 
Expression, regulation and mechanism of action of the miR-17-92 cluster in 
tumor cells (Review), International Journal of Molecular Medicine. 40 (2017) 
1624–1630, https://doi.org/10.3892/ijmm.2017.3164. 
[44] G. Srinivasan, E.A. Williamson, K. Kong, A.S. Jaiswal, G. Huang, H.-S. Kim, 
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